INMB (INmune Bio Inc. Common stock)
Insider Trading Activity
Every open-market purchase and sale reported by INMB officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-07 | David J Moss | Chief Executive Officer | M | — | — |
| 2026-07-07 | Scott Juda | Director | M | — | — |
| 2026-07-07 | Mark William Lowdell | Chief Scientific Officer | M | — | — |
| 2025-12-02 | Scott Juda | Director | A | — | — |
| 2025-12-02 | Mark William Lowdell | Chief Scientific Officer | A | — | — |
| 2025-12-02 | MARCIA ALLEN | Director | A | — | — |
| 2025-12-02 | Cory Randall Ellspermann | CFO | A | — | — |
| 2025-12-02 | James Kelly Ganjei | Director | A | — | — |
| 2025-12-02 | Timothy j Schroeder | Director | A | — | — |
| 2025-12-02 | David J Moss | Chief Executive Officer | A | — | — |
| 2025-11-18 | Mark William Lowdell | Chief Scientific Officer | MIXED | — | — |
| 2025-11-18 | Timothy j Schroeder | Director | MIXED | — | — |
| 2025-11-18 | James Kelly Ganjei | Director | MIXED | — | — |
| 2025-11-18 | MARCIA ALLEN | Director | MIXED | — | — |
| 2025-11-18 | David J Moss | Chief Executive Officer | MIXED | — | — |
| 2025-11-18 | Scott Juda | Director | MIXED | — | — |
| 2025-11-18 | Cory Randall Ellspermann | Interim CFO | MIXED | — | — |
| 2024-12-09 | Mark William Lowdell | Chief Scientific Officer | A | — | — |
| 2024-12-09 | Raymond Joseph Tesi | President and CEO | A | — | — |
| 2024-12-09 | David J Moss | Chief Financial Officer | A | — | — |
| 2024-12-09 | James Kelly Ganjei | Director | A | — | — |
| 2024-12-09 | Timothy j Schroeder | Director | A | — | — |
| 2024-12-09 | MARCIA ALLEN | Director | A | — | — |
| 2024-12-09 | Scott Juda | Director | A | — | — |
| 2024-09-30 | David J Moss | Chief Financial Officer | Buy | — | — |
| 2024-09-16 | David J Moss | Chief Financial Officer | Buy | — | — |
| 2024-09-16 | Raymond Joseph Tesi | President and CEO | Buy | — | — |
| 2024-06-26 | Scott Juda | Director | Buy | — | — |
| 2024-06-12 | Raymond Joseph Tesi | President and CEO | A | — | — |
| 2024-05-16 | Raymond Joseph Tesi | President and CEO | A | — | — |
| 2024-05-16 | Mark William Lowdell | Chief Scientific Officer | A | — | — |
| 2024-05-16 | MARCIA ALLEN | Director | A | — | — |
| 2024-05-16 | Timothy j Schroeder | Director | A | — | — |
| 2024-05-16 | Edgardo Jr Baracchini | Director | A | — | — |
| 2024-05-16 | David J Moss | Chief Financial Officer | A | — | — |
| 2024-05-16 | Scott Juda | Director | A | — | — |
| 2024-05-16 | James Kelly Ganjei | Director | A | — | — |
| 2024-04-24 | Scott Juda | Director | Buy | — | — |
| 2024-04-24 | Raymond Joseph Tesi | President and CEO | Buy | — | — |
| 2024-04-24 | Mark William Lowdell | Chief Scientific Officer | Buy | — | — |
| 2024-04-24 | David J Moss | CFO, Treasurer & Secretary | Buy | — | — |
| 2024-04-23 | David J Moss | CFO, Treasurer & Secretary | A | — | — |
| 2024-04-23 | Mark William Lowdell | Chief Scientific Officer | A | — | — |
| 2024-04-23 | Raymond Joseph Tesi | President and CEO | A | — | — |
| 2024-04-23 | Scott Juda | Director | A | — | — |
| 2023-11-13 | Scott Juda | Director | Buy | — | — |
| 2023-07-14 | Timothy j Schroeder | Director | Sell | — | — |
| 2023-03-20 | David J Moss | CFO, Treasurer & Secretary | Buy | — | — |
| 2023-02-21 | Timothy j Schroeder | Director | A | — | — |
| 2023-02-21 | David J Moss | CFO, Treasurer & Secretary | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 1,885,533 | — |
| — | President and CEO | 1,554,106 | — |
| — | Chief Scientific Officer | 1,518,017 | — |
| — | Chief Executive Officer | 1,294,883 | — |
| — | 10%+ Owner | 910,000 | — |
| — | Director | 158,007 | — |
| — | Director | 82,187 | — |
| — | Director | 17,793 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the INMB quote page; the site-wide leaderboard is on the insider transactions hub.